PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

PTCT reports robust Q1 results, faces regulatory submission challenges

PTCT's strong financial performance and progress in clinical studies position the company for future growth. While facing challenges related to regulatory submissions and FDA requests, the company is focused on addressing these issues and leveraging opportunities presented by upcoming clinical study results and portfolio review.

PTC Therapeutics reports robust Q2 revenue and navigates regulatory challenges

PTC Therapeutics showcased strong financial performance, a promising pipeline, and a proactive approach to regulatory challenges. The company's focus on cost savings and strategic prioritization aligns with its goal of achieving revenue guidance and maximizing market opportunities.

PTC Therapeutics secures $1.5B financing, updates DMD revenue guidance

PTC Therapeutics' Q3 2023 earnings call highlighted robust financial performance, a strengthened financial position, regulatory challenges, and promising opportunities for future growth. The company's strategic focus on key programs and ongoing studies positions it for continued progress and potential market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Atara Biotherapeutics

Biohaven Pharmaceutical Hld

CymaBay Therapeutics

Marinus Pharmaceuticals

Solid Biosciences

Telesis Bio Inc

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

7 Disruptive Biotech Stocks to Buy for 2025

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: PTC Therapeutics (PTCT) Q1 Earnings Expected to Decline

Bristol-Myers

Genfit - ADR

Intercept Pharma

Madrigal Pharmaceuticals

Novartis

Roche Holding AG

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Intercept Pharmaceuticals Inc.

FDA Decisions on 5 Drugs Expected in 2nd Quarter

Corbus Pharmaceuticals Holdings

Gilead Sciences

Galapagos

A growing number of Covid-19 cases could frustrate biotech companies' efforts to enroll patients in clinical studies, an analyst said Tuesday.

The Surprising Impact Coronavirus Will Have On Biotech Companies

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q4 2019 Results - Earnings Call Transcript

Investors are showing their displeasure with the biotech's latest clinical update.

Why PTC Therapeutics Stock Is Plummeting Today

Shares of PTC Therapeutics crashed Thursday after the biotech company unveiled disappointing Phase 3 results for its Biogen-rivaling experimental spinal muscular atrophy drug, risdiplam.
The post Why This Biotech Stock Crashed And Prodded Biogen Into A Two-Day Run appeared first on Investor's Business Daily.

Why This Biotech Stock Crashed And Prodded Biogen Into A Two-Day Run

ANI Pharma

Immunomedics

Mirati Therapeutics

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

4 Drug/Biotech Outperformers That May Lose Steam in 2020

eHealth

Momenta Pharmaceuticals

PDC Energy Inc

Stitch Fix

What a year 2019 was for investors. The major indexes are all up over 20%, and markets are hitting record highs.

5 Top SunTrust Stock Picks for 2020 With Massive Upside Potential

PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q3 2019 Results - Earnings Call Transcript

The company more than doubled its cash balance from the end of June with two fundraising transactions.

Here's Why PTC Therapeutics Fell 24.1% in September

The business is raising cash through two offerings: one of debt and one of common stock.

Here's Why PTC Therapeutics Fell as Much as 12.5% Today

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2019 Results - Earnings Call Transcript

PTC Therapeutics, Inc. announced Friday that the Food and Drug Administration approved a label expansion for the drug Emflaza to include younger patients with Duchenne muscular dystrophy who are between 2 and 5 years old.

PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients

PTC Therapeutics stock jumped Tuesday after its Roche-partnered spinal muscular atrophy treatment showed positive test results — leading shares of rival Ionis Pharmaceuticals to slip.

This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen

PTC Therapeutics Inc.'s (PTCT) CEO Stuart Peltz on Q1 2019 Results - Earnings Call Transcript

News for PTC Therapeutics Stock (PTCT)